GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (LTS:0A5J) » Definitions » Gross-Profit-to-Asset %

Dermapharm Holding SE (LTS:0A5J) Gross-Profit-to-Asset % : 38.01% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Dermapharm Holding SE Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Dermapharm Holding SE's annualized Gross Profit for the quarter that ended in Mar. 2025 was €797 Mil. Dermapharm Holding SE's average Total Assets over the quarter that ended in Mar. 2025 was €2,096 Mil. Therefore, Dermapharm Holding SE's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 38.01%.


Dermapharm Holding SE Gross-Profit-to-Asset % Historical Data

The historical data trend for Dermapharm Holding SE's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Gross-Profit-to-Asset % Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.85 47.18 46.87 40.25 36.18

Dermapharm Holding SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.77 32.57 36.28 36.77 38.01

Competitive Comparison of Dermapharm Holding SE's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Gross-Profit-to-Asset % falls into.


;
;

Dermapharm Holding SE Gross-Profit-to-Asset % Calculation

Dermapharm Holding SE's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=767.07/( (2160.673+2080.019)/ 2 )
=767.07/2120.346
=36.18 %

Dermapharm Holding SE's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=796.74/( (2080.019+2111.738)/ 2 )
=796.74/2095.8785
=38.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Dermapharm Holding SE Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.

Dermapharm Holding SE Headlines

No Headlines